ArticleEJHaem2020

Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib.

Paul G Richardson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.